US Faces Prolonged Shortage of Congenital Syphilis Treatment

The United States is experiencing a critical shortage of Bicillin L-A, the sole domestic treatment for congenital syphilis, with supplies not anticipated to normalize until late 2027. This scarcity follows a 2025 manufacturing recall by Pfizer. The FDA has authorized temporary imports of an alternative drug to address the issue, as congenital syphilis cases have significantly risen.